Locally Advanced BCC

About
Advanced BCC

Advanced BCC is a serious disease with historically limited treatment options1,2

BCC is the most common cancer, with greater than 2 million new cases annually in the US
  • >2 million new cases per year
    BCC is the most common cancer, with >2 million new cases diagnosed annually in the US3,4
  • 20k advanced cases per year
    While most patients with early-stage BCC are cured with complete surgical excision and/or radiation, ≈20,000 cases progress to advanced BCC each year1,3-6
  • No longer candidates
    Some of these patients are no longer candidates for curative surgery and/or curative radiation3,7
HHIs are approved for patients with advanced BCC who are no longer candidates for curative surgery and/or curative radiation
  • HHI

    Hedgehog inhibitors are approved for patients with advanced BCC who are no longer candidates for curative surgery and/or curative radiation7,8

    There is a significant unmet need for patients who discontinue HHI therapy or for whom HHI therapy is inappropriate7-12

Guidelines unanimously recommend a multidisciplinary approach to the management of laBCC9,13-14

  • American Academy of Dermatology (AAD)9
  • European Dermatology Forum (EDF)13
  • European Association of Dermatology Oncology (EADO)13
  • European Organisation for Research and Treatment of Cancer (EORTC)13
  • National Comprehensive Cancer Network® (NCCN®)14¶

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

NCCN Guidelines® for Basal Cell Skin Cancer V.2.2022 include cemiplimab-rwlc (LIBTAYO®) as recommended systemic therapy option for appropriate patients with locally advanced BCC

Category 2A9# recommended systemic therapy option

Cemiplimab-rwlc (LIBTAYO®) for locally advanced BCC**
patients previously treated with an HHI or for whom an HHI is not appropriate

Only recommended PD-1 inhibitor for appropriate patients with locally advanced BCC

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

  • NCCN Guidelines® do not specify a specific list of disciplines that must be included in a multidisciplinary tumor board.
  • #Category 2A recommendation is based upon lower-level evidence; there is uniform NCCN consensus that the intervention is appropriate. All recommendations are Category 2A unless otherwise specified.
  • **Locally advanced BCC is defined as primary or recurrent local disease that is not amendable to surgery or RT.14
  • BCC=basal cell carcinoma; DOR=duration of response; ICR=independent central review; laBCC=locally advanced BCC; ORR=objective response rate; PD‑1=programmed death receptor-1; RT=radiation therapy; TTR=time to response.

NCCN is a registered trademark of the National Comprehensive Cancer Network® (NCCN®).